The First US Gene Therapy Maker Innovates On Pricing And Reimbursement
Executive Summary
Spark priced the gene therapy Luxturna for inherited blindness at $850,000 for treatment of both eyes, below the $1m price some expected, and revealed pioneering market access plans. CEO Jeffrey Marrazzo and Harvard Pilgrim's Michael Sherman talked with Scrip about the details.
You may also be interested in...
Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
Gene Therapy: What To Expect Now And In The Future
The US FDA could approve as many new gene therapies in 2023 as it has in the previous five years. Development in the field has rapidly accelerated, but still faces hurdles.
Roche $4.8bn Buy Sparks Hemophilia Gene Therapy Race
The Swiss major's proposed acquisition of Spark Therapeutics gives it a leading seat at the table in the emerging field of gene therapy.